DSpace Repository

The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents

Show simple item record

dc.contributor.author Tufan, Ahmet Çevik
dc.contributor.author Satıroğlu-Tufan, Naciye Lale
dc.date.accessioned 2019-08-16T11:38:04Z
dc.date.available 2019-08-16T11:38:04Z
dc.date.issued 2005
dc.identifier.issn 1568-0096
dc.identifier.uri https://hdl.handle.net/11499/4858
dc.identifier.uri https://doi.org/10.2174/1568009054064624
dc.description.abstract Angiogenesis, the formation of new blood vessels, is essential for tumor growth, progression and metastasis. The development of agents that target tumor vasculature is ultimately dependent on the availability of appropriate preclinical screening assays. The chorioallantoic membrane (CAM) assay is well established and widely used as a model to examine angiogenesis, and anti-angiogenesis. This review 1) summarizes the currently used angiogenesis assays and the importance of CAM model among them; 2) summarizes the current knowledge about the development and structure of the CAM's capillary bed; 3) reports findings regarding the role played by molecular signaling pathways in angiogenesis process; 4) discusses the use, advantages and limitations of the CAM as a model for studying tumor angiogenesis and invasiveness, as well as development of angiogenic and/or anti-angiogenic agents; 5) discusses the importance of standardization of the major methodologies for all aspects of the use of the CAM in angiogenesis-related studies; 6) and finally, summarizes major findings regarding the agents developed by the use of CAM model in the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. © 2005 Bentham Science Publishers Ltd. en_US
dc.language.iso en en_US
dc.relation.ispartof Current Cancer Drug Targets en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject 1,4 phenylenebis(methylene)selenocyanate en_US
dc.subject acetylsalicylic acid en_US
dc.subject alpha cyclodextrin en_US
dc.subject alpha thymosin peptide en_US
dc.subject amiloride en_US
dc.subject angiogenesis inhibitor en_US
dc.subject angiogenin antibody en_US
dc.subject angiopoietin receptor en_US
dc.subject angiostatin en_US
dc.subject angiotensinogen en_US
dc.subject angiotensinogen derivative en_US
dc.subject anthracycline derivative en_US
dc.subject apomorphine en_US
dc.subject arylsulfatase inhibitor en_US
dc.subject basic fibroblast growth factor antibody en_US
dc.subject beta cyclodextrin en_US
dc.subject bleomycin en_US
dc.subject carbohydrate derivative en_US
dc.subject cell adhesion molecule antagonist en_US
dc.subject cortisone en_US
dc.subject cyclosporin en_US
dc.subject cytokine en_US
dc.subject doxorubicin en_US
dc.subject endostatin en_US
dc.subject fenretinide en_US
dc.subject fibroblast growth factor en_US
dc.subject fibroblast growth factor 2 en_US
dc.subject gm 1474 en_US
dc.subject goniodomin A en_US
dc.subject heparan sulfate en_US
dc.subject heparanase inhibitor en_US
dc.subject heparin en_US
dc.subject homocysteine en_US
dc.subject hyaluronic acid binding protein en_US
dc.subject indinavir en_US
dc.subject indole derivative en_US
dc.subject interleukin 2 en_US
dc.subject kininogen en_US
dc.subject kininogen derivative en_US
dc.subject kininostat en_US
dc.subject matrix metalloproteinase inhibitor en_US
dc.subject metastatin en_US
dc.subject microsomal aminopeptidase inhibitor en_US
dc.subject mitogen activated protein kinase p38 en_US
dc.subject monoclonal antibody en_US
dc.subject motuporanine en_US
dc.subject nitric oxide en_US
dc.subject ornithine decarboxylase inhibitor en_US
dc.subject pentosan polysulfate en_US
dc.subject peptide derivative en_US
dc.subject platelet derived growth factor en_US
dc.subject protamine en_US
dc.subject protamine sulfate en_US
dc.subject proteasome inhibitor en_US
dc.subject protein tyrosine kinase inhibitor en_US
dc.subject prothrombin en_US
dc.subject purine derivative en_US
dc.subject retinoid en_US
dc.subject ruthenium red derivative en_US
dc.subject saquinavir en_US
dc.subject scatter factor en_US
dc.subject somatostatin en_US
dc.subject somatostatin derivative en_US
dc.subject spironolactone en_US
dc.subject squalamine en_US
dc.subject steroid en_US
dc.subject stromelysin en_US
dc.subject sulindac en_US
dc.subject suramin en_US
dc.subject suramin derivative en_US
dc.subject tamoxifen en_US
dc.subject thalidomide en_US
dc.subject thrombocyte factor 4 en_US
dc.subject thymidine phosphorylase inhibitor en_US
dc.subject titanocene dichloride en_US
dc.subject transforming growth factor alpha en_US
dc.subject transforming growth factor beta en_US
dc.subject u 995 en_US
dc.subject unclassified drug en_US
dc.subject vasculotropin en_US
dc.subject vasculotropin antibody en_US
dc.subject vasculotropin diphtheria toxin conjugate en_US
dc.subject vasculotropin receptor 2 en_US
dc.subject angiogenesis en_US
dc.subject apoptosis en_US
dc.subject assay en_US
dc.subject cancer invasion en_US
dc.subject capillary en_US
dc.subject cell culture en_US
dc.subject cell growth en_US
dc.subject cell migration en_US
dc.subject cell proliferation en_US
dc.subject cell viability en_US
dc.subject chemokinesis en_US
dc.subject chick embryo en_US
dc.subject chorioallantois en_US
dc.subject cost effectiveness analysis en_US
dc.subject DNA synthesis en_US
dc.subject drug mechanism en_US
dc.subject embryo development en_US
dc.subject endothelium cell en_US
dc.subject fetus membrane en_US
dc.subject in vivo study en_US
dc.subject mesoderm en_US
dc.subject metastasis en_US
dc.subject model en_US
dc.subject morphometrics en_US
dc.subject nonhuman en_US
dc.subject organ culture en_US
dc.subject protein family en_US
dc.subject protein function en_US
dc.subject review en_US
dc.subject scoring system en_US
dc.subject standardization en_US
dc.subject tumor growth en_US
dc.subject tumor vascularization en_US
dc.subject validation process en_US
dc.subject Angiogenesis Inhibitors en_US
dc.subject Animals en_US
dc.subject Chick Embryo en_US
dc.subject Chorioallantoic Membrane en_US
dc.subject Drug Evaluation, Preclinical en_US
dc.subject Humans en_US
dc.subject Models, Biological en_US
dc.subject Neoplasm Invasiveness en_US
dc.subject Neoplasms en_US
dc.subject Neovascularization, Pathologic en_US
dc.title The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents en_US
dc.type Review en_US
dc.identifier.volume 5 en_US
dc.identifier.issue 4 en_US
dc.identifier.startpage 249
dc.identifier.startpage 249 en_US
dc.identifier.endpage 266 en_US
dc.authorid 0000-0001-9399-0960
dc.identifier.doi 10.2174/1568009054064624
dc.relation.publicationcategory Diğer en_US
dc.identifier.pmid 15975046 en_US
dc.identifier.scopus 2-s2.0-21344456550 en_US
dc.identifier.wos WOS:000230100100002 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record